Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

Cytek Biosciences, Inc. (CTKB)

Compare
3.7200
-0.2700
(-6.77%)
At close: April 3 at 4:00:01 PM EDT
Loading Chart for CTKB
  • Previous Close 3.9900
  • Open 3.8500
  • Bid 3.6800 x 300
  • Ask 3.7500 x 200
  • Day's Range 3.7100 - 3.9000
  • 52 Week Range 3.7100 - 7.6300
  • Volume 946,124
  • Avg. Volume 869,054
  • Market Cap (intraday) 476.521M
  • Beta (5Y Monthly) 1.41
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0500
  • Earnings Date May 6, 2025 - May 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.90

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

cytekbio.com

648

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CTKB

View More

Performance Overview: CTKB

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CTKB
42.68%
S&P 500 (^GSPC)
8.25%

1-Year Return

CTKB
43.29%
S&P 500 (^GSPC)
3.55%

3-Year Return

CTKB
65.81%
S&P 500 (^GSPC)
18.71%

5-Year Return

CTKB
81.49%
S&P 500 (^GSPC)
116.85%

Compare To: CTKB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CTKB

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    476.52M

  • Enterprise Value

    215.68M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.42

  • Price/Book (mrq)

    1.20

  • Enterprise Value/Revenue

    1.08

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -3.00%

  • Return on Assets (ttm)

    -2.91%

  • Return on Equity (ttm)

    -1.53%

  • Revenue (ttm)

    200.45M

  • Net Income Avi to Common (ttm)

    -6.02M

  • Diluted EPS (ttm)

    -0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    277.86M

  • Total Debt/Equity (mrq)

    4.30%

  • Levered Free Cash Flow (ttm)

    36.25M

Research Analysis: CTKB

View More

Company Insights: CTKB

Research Reports: CTKB

View More

People Also Watch